Cover Image
市場調查報告書

Siena Biotech S.p.A.:產品平台分析

Siena Biotech S.p.A. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 192818
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
Siena Biotech S.p.A.:產品平台分析 Siena Biotech S.p.A. - Product Pipeline Review - 2014
出版日期: 2014年06月10日 內容資訊: 英文 35 Pages
簡介

Siena Biotech S.p.A.ha是開發中樞神經系統(CNS)的退化性疾病及增生性疾病之治療性介入所用醫藥品的開發企業。

本報告提供Siena Biotech S.p.A.的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Siena Biotech S.p.A.的基本資料

Siena Biotech S.p.A.概要

  • 主要資訊
  • 企業資料

Siena Biotech S.p.A.:R&D概要

  • 主要的治療範圍

Siena Biotech S.p.A.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Siena Biotech S.p.A.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Siena Biotech S.p.A.:藥物簡介

  • selisistat
  • Alpha 7 Nicotinic Agonist
  • SEN-15924
  • SEN-34625
  • Tankyrase/Wnt Inhibitors
  • Chemokine Receptor Type 4 Antagonists for Cancer
  • Glutaminyl Cyclase Inhibitors
  • Huntingtin Toxicity Inhibitors
  • Monoclonal Antibody for Bone Diseases
  • S1P3 Antagonist Progam
  • SEN-794
  • Small Molecule for Huntington's Disease

Siena Biotech S.p.A.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Siena Biotech S.p.A.:暫停中的計劃

Siena Biotech S.p.A.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04906CDB

Global Markets Direct's, 'Siena Biotech S.p.A. - Product Pipeline Review - 2014', provides an overview of the Siena Biotech S.p.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Siena Biotech S.p.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Siena Biotech S.p.A. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Siena Biotech S.p.A.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Siena Biotech S.p.A.'s pipeline products

Reasons to buy

  • Evaluate Siena Biotech S.p.A.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Siena Biotech S.p.A. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Siena Biotech S.p.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Siena Biotech S.p.A. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Siena Biotech S.p.A.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Siena Biotech S.p.A. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Siena Biotech S.p.A. Snapshot
    • Siena Biotech S.p.A. Overview
    • Key Information
    • Key Facts
  • Siena Biotech S.p.A. - Research and Development Overview
    • Key Therapeutic Areas
  • Siena Biotech S.p.A. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Siena Biotech S.p.A. - Pipeline Products Glance
    • Siena Biotech S.p.A. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Siena Biotech S.p.A. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Siena Biotech S.p.A. - Drug Profiles
    • selisistat
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Alpha 7 Nicotinic Agonist
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SEN-15924
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SEN-34625
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Tankyrase/Wnt Inhibitors
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Chemokine Receptor Type 4 Antagonists for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Glutaminyl Cyclase Inhibitors
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Huntingtin Toxicity Inhibitors
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Bone Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S1P3 Antagonist Progam
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SEN-794
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Huntington's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Siena Biotech S.p.A. - Pipeline Analysis
  • Siena Biotech S.p.A. - Pipeline Products by Target
  • Siena Biotech S.p.A. - Pipeline Products by Route of Administration
  • Siena Biotech S.p.A. - Pipeline Products by Molecule Type
  • Siena Biotech S.p.A. - Pipeline Products by Mechanism of Action
  • Siena Biotech S.p.A. - Dormant Projects
  • Siena Biotech S.p.A. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Siena Biotech S.p.A., Key Information
  • Siena Biotech S.p.A., Key Facts
  • Siena Biotech S.p.A. - Pipeline by Indication, 2014
  • Siena Biotech S.p.A. - Pipeline by Stage of Development, 2014
  • Siena Biotech S.p.A. - Monotherapy Products in Pipeline, 2014
  • Siena Biotech S.p.A. - Phase II, 2014
  • Siena Biotech S.p.A. - Preclinical, 2014
  • Siena Biotech S.p.A. - Discovery, 2014
  • Siena Biotech S.p.A. - Pipeline by Target, 2014
  • Siena Biotech S.p.A. - Pipeline by Route of Administration, 2014
  • Siena Biotech S.p.A. - Pipeline by Molecule Type, 2014
  • Siena Biotech S.p.A. - Pipeline Products by Mechanism of Action, 2014
  • Siena Biotech S.p.A. - Dormant Developmental Projects,2014

List of Figures

  • Siena Biotech S.p.A. - Pipeline by Top 10 Indication, 2014
  • Siena Biotech S.p.A. - Pipeline by Stage of Development, 2014
  • Siena Biotech S.p.A. - Monotherapy Products in Pipeline, 2014
  • Siena Biotech S.p.A. - Pipeline by Top 10 Target, 2014
  • Siena Biotech S.p.A. - Pipeline by Top 10 Route of Administration, 2014
  • Siena Biotech S.p.A. - Pipeline by Top 10 Molecule Type, 2014
  • Siena Biotech S.p.A. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top